Literature DB >> 28688161

Identification of patients with cancer with a high risk to develop delirium.

Elisabeth C W Neefjes1, Maurice J D L van der Vorst1,2, Bertha A T T Verdegaal1, Aartjan T F Beekman3, Johannes Berkhof4, Henk M W Verheul1.   

Abstract

Delirium deteriorates the quality of life in patients with cancer, but is frequently underdiagnosed and not adequately treated. In this study, we evaluated the occurrence of delirium and its risk factors in patients admitted to the hospital for treatment or palliative care in order to develop a prediction model to identify patients at high risk for delirium. In a period of 1.5 years, we evaluated the risk of developing delirium in 574 consecutively admitted patients with cancer to our academic oncology department with the Delirium Observation Screening Scale. Risk factors for delirium were extracted from the patient's chart. A delirium prediction algorithm was constructed using tree analysis, and validated with fivefold cross-validation. A total of 574 patients with cancer were acutely (42%) or electively (58%) admitted 1733 times. The incidence rate of delirium was 3.5 per 100 admittances. Tree analysis revealed that the predisposing factors of an unscheduled admittance and a metabolic imbalance accurately predicted the development of delirium. In this group the incidence rate of delirium was 33 per 100 patients (1:3). The AUC of the model was 0.81, and 0.65 after fivefold cross-validation. We identified that especially patients undergoing an unscheduled admittance with a metabolic imbalance do have a clinically relevant high risk to develop a delirium. Based on these factors, we propose to evaluate preventive treatment of these patients when admitted to the hospital in order to improve their quality of life.
© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Cancer; delirium; epidemiology; medical oncology; prevention; risk factors

Mesh:

Year:  2017        PMID: 28688161      PMCID: PMC5548884          DOI: 10.1002/cam4.1106

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


Introduction

Delirium is a common problem in hospital care, especially for patients with cancer as well as elderly and frail patients 1. It is a syndrome of brain dysfunction characterized by a disturbance in attention, awareness, and cognition, with a rapid onset that is caused by an underlying medical condition 2, 3. The occurrence of delirium depends on a combination of vulnerability (predisposing factors) and precipitating factors that trigger the development of delirium 4. Risk factors include aging, cognitive impairment, and a history of delirium, and screening for delirium in patients at risk may be of help to reduce suffering from delirium 5, 6, 7, 8, 9, 10, 11. Data on the incidence and prevalence of delirium in literature range from a 5% prevalence rate upon admission to a geriatric hospital ward 12 up to an incidence rate of 88% in patients dying from cancer 8. This diversity in incidence and prevalence rates indicates that it is a serious problem for patients with cancer especially when terminally ill. In recent publications it has been suggested that prophylactic treatment with antipsychotics should be considered to prevent delirium 13, 14, 15, 16, 17, but due to the varying incidence rates of delirium and the sometimes severe side‐effects of these medicines (primarily haloperidol) 18 there is reluctance to apply preventive treatment to all patients with cancer admitted to the hospital. It would be of clinical significance if one could determine which patients are likely to develop delirium at admission in order to select patients who might benefit from prophylactic treatment. In this study, the primary aim was to evaluate the occurrence of delirium and its risk factors in patients with cancer admitted to the hospital for treatment or palliative care in order to develop a prediction model to identify patients at high risk for delirium.

Methods

This retrospective study was conducted in all patients with solid malignancies admitted to our medical oncology ward of the VUmc Cancer Center Amsterdam (CCA), VU University Medical Center, between Jan 1st 2011 and June 30th 2012. For each patient the following data were collected from medical charts: baseline characteristics, presence of delirium, and its risk factors throughout the entire admission. The study was conducted in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Because of the retrospective character of this study no additional informed consent could be obtained and a waiver was obtained from the medical ethical committee. Screening for delirium was performed twice a week during three consecutive nursing shifts according to standard hospital procedures using the Delirium Observation Screening Scale (DOSS) 12. The DOSS is a validated 13‐item nurse‐rated screening instrument for delirium that is commonly used in Dutch hospitals. Scores range from 0 to 13 points, with ≥ 3 as a cut‐off for delirium. It has sensitivity and specificity rates of 92% and 82%, respectively 19. Delirium was recorded as present if the diagnosis was noted in the patient chart, or if the patient had a DOSS score ≥ 3 without a rejection of the delirium diagnosis written down in the chart. The following risk factors were assessed: age > 70 years, alcohol or drug abuse, hearing, visual and/or cognitive impairment, history of delirium, high doses of opioids (>90 mg of oral morphine or equivalent), corticosteroids (>15 mg dexamethasone or equivalent), and/or sedatives (>2 mg lorazepam or equivalent), infections, postoperative state (until discharge of major surgery), constipation (note of constipation or note of delayed stool production for >48 hours), urinary retention, tumor burden and location, organ failure, and metabolic disturbances 4, 5, 6, 7, 8, 9, 10. In detail these risk factors are depicted in table 1. To avoid dependence the first admission with or without delirium for each patient was used for comparisons.
Table 1

Predisposing and precipitating factors for delirium

Predisposing factors
Age > 70 years
Alcohol or drug abuse
Hearing impairment
Visual impairment
History of delirium
Cognitive impairment
Predisposing and precipitating factors for delirium

Development of a delirium prediction algorithm

Based on the predisposing factors and the grouped variables for the precipitating factors, a prediction algorithm was developed. For the development of this prediction algorithm, the groups were defined irrespective of the prevalence rates of the individual factors to limit the number of factors included (see Table 1). Grouped variables were defined positive if any of the factors in this group was present. Eastern Co‐operative Oncology Group (ECOG) performance status (0–2 vs. 3–4), palliative or curative treatment intention, and whether or not an admission was scheduled were also included in the prediction algorithm. For prediction models, it is recommended that the number of events should ideally be 10‐fold higher than the number of variables included in the model 20. Therefore, we enriched the database with 46 extra delirium cases that were consecutively diagnosed with DOSS screening between July 2012 and September 2013 (Table 2). These baseline characteristics of these cases did not significantly differ from the patients with delirium in the original dataset. The enriched database is suitable for the calculation of odds ratios and the identification of predictors, but not for the calculation of absolute risks 21. The absolute risks were calculated from the original database.
Table 2

Patients included in prediction algorithm

Delirium =No delirium n = Total n =
Study period52522574
Extra delirium casesa 4646
Total98522620

For adequate power in the development of the delirium prediction algorithm, data on the predisposing and precipitating factors of 46 patients who developed delirium between July 2012 and September 2013 were added to the original dataset. These data were only used for the development of this algorithm. Absolute risks at delirium reported in the article were calculated with the original dataset.

Patients included in prediction algorithm For adequate power in the development of the delirium prediction algorithm, data on the predisposing and precipitating factors of 46 patients who developed delirium between July 2012 and September 2013 were added to the original dataset. These data were only used for the development of this algorithm. Absolute risks at delirium reported in the article were calculated with the original dataset.

Statistical analysis

Statistical evaluation of differences between nondelirious and delirious patients was performed with a χ 2‐test, the Fisher exact test, or the Student's t‐test, whenever appropriate. Because of the multiple comparisons an adjusted P = 0.01 was considered statistically significant. To create a delirium risk prediction algorithm that can be easily implemented in the clinic, we used a tree analysis method 22. All predisposing and the grouped precipitating factors for delirium were used in this tree analysis, irrespective of the χ 2‐test and students t‐test results, to predict the risk of developing delirium in subgroups of patients. The number of splits in the tree was chosen in order to minimize the cross‐validated prediction error. Fivefold cross‐validation was used for validation of the algorithm. For both the original and the cross‐validated model the area under the curve (AUC) was calculated. Data were collected in the web‐based database system OpenClinica version 3.1.2. Statistical tests were performed with SPSS version 20.0. The prediction algorithm was constructed with the software package R program Rpart (version 3.1).

Results

A total of 574 individual patients were admitted 1733 times during the study period (mean 2.95 admittances per patient, ranging from 1 to 22 admissions per patient). Sixty delirium episodes were recorded for 52 individual patients, which resulted in a delirium incidence rate of 3.5 per 100 admittances. Nine percent of all patients admitted in this period developed delirium.

Patient characteristics

Of all 1733 admittances, 1003 admittances (57.9%) were scheduled. The mean age of admitted patients was 60 years (SD 13.1) and 60% of the patients were male. Compared with patients who did not develop delirium, patients who developed delirium were significantly older (mean age of 59 vs. 67 years, respectively (P < 0.001)), had a worse ECOG performance status at admittance, and more often received treatment with palliative intention or palliative care only. Ninety‐four percent of the patients who developed delirium had an unscheduled admittance, compared to 49% of the patients who did not develop delirium (P < 0.001). In 10 of the 730 unscheduled admittances the indication for the admittance was suspected delirium (n = 2), confusion (n = 5), or drowsiness (n = 3). Seven of these patients were diagnosed with delirium in the hospital. Patients with delirium stayed longer in the hospital, and the outcome was worse. In Table 3, these data are shown in detail.
Table 3

Patient characteristics

Total = 1733%Total first admittance n=574%No delirium = 522%Delirium = 52% a OR95%CI of OR
AgeMean (SD)57.2 (14.2)60.0 (13.1)59.3 (13.3)68 (8)<0.001
GenderM:F1076:65762:38345:22960:40313:20960:4032:2062:390.831.0680.595–1.919
Tumor typeGastrointestinal6453719634179341733
Genitourethral3692112922119231019
Skin503346255927
Lung20202000
Head & Neck369211081910019815
Brain81614124
Sarcoma120720420400
Breast976539489510
Other734265255120.009
ECOG performance status0223139617961800
19645626246252481019
23852214625127241937
3132856104081631
429214271714<0.001
Length of stayDays (Median (IQR))3 (2–6)4 (2–7)4 (2–7)10 (5–16)<0.001
OutcomeAlive16929854996508974179
Deceased4122541431121<0.0019.7354.155–22.809
Treatment intentionCurative626361743016632815
Palliative110764400703566844850.012.0671.079–3.958
Indication for admittanceScheduled admittance100358270472675136
Chemotherapy 88551209362084012
Diagnostic procedures68440739712
Intervention50321420412
Unscheduled admittance7304230453255494994<0.00117.1025.264–550.560
Clinical symptoms5353125144209404281
Complication19511539469714
Delirium TypeHyperactive1121
Hypoactive2039
Mixed1835
Unknownb 36

P–values of the comparison between the patients with delirium and the patients without delirium.

Delirium type could not be determined from the information in the patient chart.

Patient characteristics P–values of the comparison between the patients with delirium and the patients without delirium. Delirium type could not be determined from the information in the patient chart.

Predisposing and precipitating factors

The most prevalent predisposing factors in this group of patients were age >70 and alcohol/drug abuse (21% and 8%, respectively). Although all factors were previously defined as predisposing factors, only age >70 significantly correlated with the development of delirium in univariate analysis (P < 0.001). The most prevalent precipitating factors were high doses of psychotropic medication, infection, constipation, and metabolic imbalance (25%, 22%, 19%, and 18%, respectively). The precipitating factors infection, constipation, urinary retention, organ failure, and metabolic imbalance were significantly related with the presence of delirium (P < 0.001) (Table 4).
Table 4

Prevalence of predisposing and precipitating factors

Total n = 574%No delirium = 522%Delirium = 52% P=Odds Ratio95% confidence interval OR
Predisposing factors
Age > 70No45279421813160
Yes12221101192140<0.001a 2.8241.557–5.119
Alcohol/drug abuseNo52692480924689
Yes4884286120.431.4910.602–3.693
Hearing difficultyNo55697508974892
Yes183143480.073.0240.958–9.549
Visual impairmentNo55997511984892
Yes153112480.043.8711.187–12.624
History of deliriumNo569995179952100
Yes5151000.99
Cognitive impairmentNo56298514994892
Yes12282480.025.3541.555–18.431
Precipitating factors
High doses of psychotropic medicationNo42875397763160
Yes 146251252421400.012.1511.193–3.878
Corticosteroids437438000.03
Sedatives2952247140.013.5351.432–8.727
Opioids8615701316310.002a 2.8701.513–5.445
Alcohol/drug withdrawalNo56198511985096
Yes 132112240.331.8580.401–8.619
Alcohol122112120.990.9110.115–7.199
Sedatives000000
Other2010120.1710.2160.630–165.771
InfectionNo44878425812344
Yes 1262297192956<0.001a 5.5243.062–9.966
Fever4883979170.032.5871.175–5.694
Sepsis16392714<0.001a 8.8493.148–24.879
Urinary tract3052248150.003a 4.1241.735–9.803
Respiratory tract265173917<.001a 6.2052.610–14.750
Other305234714.013.3681.370–8.279
Intracranial neoplasmNo53894494954485
Yes 3662858150.013.2081.379–7.461
Primary tumor8151360.036.3311.469–27.287
Metastasis2441945100.062.8161.006–7.885
Carcinomatous meningitis4141000.99
Post‐operative stateNo55797509984892
Yes173132480.063.2631.024–10.398
ConstipationNo46882433833567
Yes10619891717330.006a 2.3631.268–4.405
Urinary retentionNo56098514994689
Yes142826120.001a 8.3802.788–25.192
Organ failureNo47683447862956
Yes981775142344<0.001a 4.7272.596–8.608
Liver failureNot measured77137013713
No43776401773669
Yes 601051109170.091.9710.898–4.326
Bilirubin >60 mmol/L1941534210.082.8490.903–8.983
ASAT > 150511043108180.122.0620.902–4.710
ALAT > 200245215370.471.4690.421–5.131
Pulmonary insufficiencyNot measured38066361691937
No17330148282548
Yes2141328150.017.1332.806–18.133
Renal failureNot measured15315300
No54395497954688
Yes1631026120.002a 6.6962.327–19.239
Cardiac failureNo56598514985198
Yes9282120.581.2620.155–10.294
Metabolic imbalanceNot measured20320400
No45379428822548
Yes 1011874142752<0.001a 6.5383.599–11.878
Calcium low1/41101/36200/4900.99
Calcium high8/41124/36214/4980.009a 7.9561.923–32.918
Potassium low30/550521/49849/5290.001a 4.7542.051–11.022
Potassium high5/55011/49804/528<0. 001a 41.4174.538–378.011
Sodium low25/544518/49346/51120.023.5191.330–9.311
Sodium high2/54400/49302/5140.009a
Hypoglycemia1/39500/35001/4520.11
Hyperglycemia24/395619/35054/4590.321.7000.551–5.240
Albumin low42/442924/393618/4937<0.001a 8.9274.378–18.206

P < 0.01.

Prevalence of predisposing and precipitating factors P < 0.01.

Delirium prediction algorithm

To determine the most relevant factors for the risk at delirium, a prediction algorithm by using tree analysis was developed using the enriched database. The optimum number of splits, with the lowest cross‐validated prediction error, was four. The absolute risks in the decision tree, obtained by projecting the algorithm to the original, nonenriched dataset, are depicted in Figure 1. A patient admitted to the hospital ward has a risk of 9% to develop delirium (95% CI: 6.8–11.7%). The first factor that made a major distinction between a low risk at delirium (1.1% in the original dataset, 95% CI: 0.2–3.2%) and an intermediate risk at delirium (16% in the original dataset, 95% CI: 12–21%) was whether or not an admission was scheduled. Due to the very low risk at delirium (1:100), it was deemed unnecessary to make any further distinctions within the group with a scheduled admittance. In the group with an emergency admission, a further distinction could be made between patients who did or did not have metabolic imbalances. These patients had a delirium risk of 10% and 32.5%, respectively (95% CI: 6–15%, resp. 22–44%). In the group with an unscheduled admittance combined with a metabolic imbalance (delirium risk 1:3), ECOG performance status 0–2 versus ≥3, and curative versus palliative treatment intention were further splits. The AUC of this algorithm was 0.81 (Fig. 2 upper line). We evaluated predictive validity of the algorithm by fivefold cross‐validation. This provided a lower estimate for the AUC of 0.65 (Fig. 2 lower line), as the original algorithm estimates do not correct for uncertainty in the selection of predisposing and/or precipitating factors. The sum of the sensitivity and specificity was maximal at a cut‐off with a high specificity of 85%, and a lower sensitivity of approximately 40% in the cross‐validated algorithm. This cut‐off allows for identification of a subgroup of patients with a high risk at delirium. In the algorithm, the cut‐off is the distinction between patients with an unscheduled admittance with or without metabolic imbalances.
Figure 1

Delirium prediction algorithm. This risk is defined by the combination of factors mentioned in the boxes, starting with a baseline risk of 9% when a patient is admitted to the medical oncology ward. The * refers to the square in the corner of the figure in which the metabolic imbalances are defined.

Figure 2

ROC curve of the prediction algorithm for delirium. These curves show the sensitivity and specificity of the different cut‐off points in the algorithm. AUC of the original model (blue line) is 0.81 and 0.65 for the cross‐validated model (green line).

Delirium prediction algorithm. This risk is defined by the combination of factors mentioned in the boxes, starting with a baseline risk of 9% when a patient is admitted to the medical oncology ward. The * refers to the square in the corner of the figure in which the metabolic imbalances are defined. ROC curve of the prediction algorithm for delirium. These curves show the sensitivity and specificity of the different cut‐off points in the algorithm. AUC of the original model (blue line) is 0.81 and 0.65 for the cross‐validated model (green line). We evaluated whether the factors found in this algorithm were also predictive for different admissions of the same patient by comparing the prevalence of unscheduled admittances and metabolic imbalances within patients who had both an admittance with delirium and an admittance without delirium (27/52 patients with delirium). Admittances with delirium were significantly more often unscheduled than admittances without delirium (25/27 vs. 10/27, P < 0.001). Metabolic imbalances were also more prevalent in the delirium admittance than in the admittance without delirium, but this difference was not statistically significant (12/27 vs. 6/27, P = 0.08). During the admittance with delirium, patients had a higher chance to be in the high‐risk group according to the prediction algorithm (with the combination of an unscheduled admittance and metabolic imbalances), than during the admittance without delirium (12/27 resp. 4/27, P = 0.02).

Discussion

In this study, medical data from 574 patients during 1733 admittances were evaluated to determine the occurrence of delirium and its risk factors in patients admitted to the hospital for treatment or palliative care. We found a delirium incidence rate of 3.5 per 100 admittances and determined that 9% of all patients admitted in this period developed delirium. The most frequent predisposing factors in this group of patients were age >70 and alcohol/drug abuse, whereas the most frequent precipitating factors were high doses of psychotropic medication, infection, constipation, and metabolic imbalance. Because of the large number of patients that were evaluated, it was possible to use both predisposing and precipitating factors to develop an algorithm that may be used in daily practice to identify patients with a high risk to develop a delirium. The incidence rate of 3.5% per admittance in this evaluation is lower than the 16–18% reported on similar hospital wards 6, 9. A reason for the low incidence of delirium on this ward could be that half of the admittances were scheduled for patients to receive chemotherapy or undergo other interventions, as these patients have a low risk at delirium. In the study by Ljubisavljevic and Kelly (2003) these patients were not included, and it is likely that the proportion of scheduled admittances in the study by Gaudreau et al. (2005) was also smaller. When all scheduled admissions are excluded from our dataset, the incidence rate of delirium goes up to 7.8% (57/730), which is still lower than in the aforementioned studies. Another important reason that might explain this low incidence rate could be that the mean age of the patients admitted to this ward was 60 years (only 21% of the patients were aged ≥70 years) and even the elderly patients had a good cognitive performance status, as only 2.1% of all patients had a cognitive impairment. The selected predisposing and precipitating factors were previously defined for their significant relationship with delirium, but this relationship was not confirmed for all of these factors in this study. This is most likely due to the low prevalence rates of these risk factors. In other studies logistic regression analysis to determine the influence of an individual factor on a patients risk at delirium had been used 8, 23. Although the results of these analyses indicate that a patient in whom a certain factor is present has a relatively higher risk at delirium, it does not provide the clinician with a clinical tool to clearly define the absolute risk that a specific patient has to develop delirium. Also, the effect of a combination of multiple predisposing and/or precipitating factors in the same patient is often not clear. Therefore, a prediction algorithm could be of significant clinical value to provide this information. Martinez et al. (2012) developed a prediction rule for patients admitted to the internal medicine ward 24. This prediction rule could not be applied to our medical oncology ward as the prevalence of some of the components of the prediction rule was too low (e.g., age > 85 years). We developed an alternative algorithm in which patients with high risk for delirium are rapidly identified based on an emergency admittance combined with metabolic imbalances (delirium risk 1:3) (see Fig. 1). These factors are usually available upon admission of a patients with cancer and therefore this algorithm can be easily implemented in daily clinical practice. We here propose that based on this algorithm, patients could be selected for preventive treatment for delirium 12, 13, 14, 15, 16. We do realize that our study has some limitations such as that it is a retrospective evaluation, the number of patients are rather limited to evaluate a high number (>10) of predisposing factors for delirium, and although it concerns only patients with cancer, tumor diagnosis is heterogeneous. On the other hand, the strength of this study is that no selection has been made for patients with cancer acutely admitted to the hospital and that the algorithm to determine the risk at a delirium can be easily implemented in daily practice. In future studies, preventive treatment for delirium should be evaluated for its influence on the quality of life of patients, while taking in account the added risk of treatment‐induced toxicity of such a treatment strategy. In addition, as previously advocated by others, we also highly recommend screening of acutely admitted patients for delirium 25. The specificity for the cut‐off in our algorithm is high (85%), but the sensitivity is only 40%. This means that 60% of the delirium cases would be missed when only attention is being focused at patients in the high‐risk group. Therefore, while preventive treatment of patients identified by our algorithm with a high risk of delirium needs further evaluation, also screening for delirium symptoms in the other patients with an emergency admission should be considered. In conclusion, delirium is a serious problem for patients with cancer admitted to the hospital. We identified that especially patients undergoing an unscheduled admittance with a metabolic imbalance do have a clinically relevant high risk to develop a delirium. Based on these factors, we propose to evaluate preventive treatment of these patients when admitted to the hospital in order to improve their quality of life.

Conflict of Interest

The authors have no conflicts of interest to report.
  23 in total

1.  Administration of olanzapine to prevent postoperative delirium in elderly joint-replacement patients: a randomized, controlled trial.

Authors:  Kenneth A Larsen; Susan E Kelly; Theodore A Stern; Robert H Bode; Lori Lyn Price; David J Hunter; Diane Gulczynski; Benjamin E Bierbaum; Gerard A Sweeney; Karen A Hoikala; James J Cotter; Adam W Potter
Journal:  Psychosomatics       Date:  2010 Sep-Oct       Impact factor: 2.386

2.  Haloperidol prophylaxis decreases delirium incidence in elderly patients after noncardiac surgery: a randomized controlled trial*.

Authors:  Wei Wang; Hong-Liang Li; Dong-Xin Wang; Xi Zhu; Shuang-Ling Li; Gai-Qi Yao; Kai-Sheng Chen; Xiu-E Gu; Sai-Nan Zhu
Journal:  Crit Care Med       Date:  2012-03       Impact factor: 7.598

3.  Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study.

Authors:  Kees J Kalisvaart; Jos F M de Jonghe; Marja J Bogaards; Ralph Vreeswijk; Toine C G Egberts; Bart J Burger; Piet Eikelenboom; Willem A van Gool
Journal:  J Am Geriatr Soc       Date:  2005-10       Impact factor: 5.562

4.  Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study.

Authors:  P G Lawlor; B Gagnon; I L Mancini; J L Pereira; J Hanson; M E Suarez-Almazor; E D Bruera
Journal:  Arch Intern Med       Date:  2000-03-27

5.  Fast, systematic, and continuous delirium assessment in hospitalized patients: the nursing delirium screening scale.

Authors:  Jean-David Gaudreau; Pierre Gagnon; François Harel; Annie Tremblay; Marc-André Roy
Journal:  J Pain Symptom Manage       Date:  2005-04       Impact factor: 3.612

Review 6.  Does this patient have delirium?: value of bedside instruments.

Authors:  Camilla L Wong; Jayna Holroyd-Leduc; David L Simel; Sharon E Straus
Journal:  JAMA       Date:  2010-08-18       Impact factor: 56.272

7.  Risk factors for development of delirium among oncology patients.

Authors:  Vladan Ljubisavljevic; Brian Kelly
Journal:  Gen Hosp Psychiatry       Date:  2003 Sep-Oct       Impact factor: 3.238

Review 8.  Palliating delirium in patients with cancer.

Authors:  Augusto Caraceni; Fabio Simonetti
Journal:  Lancet Oncol       Date:  2009-02       Impact factor: 41.316

9.  The Delirium Observation Screening Scale: a screening instrument for delirium.

Authors:  Marieke J Schuurmans; Lillie M Shortridge-Baggett; Sijmen A Duursma
Journal:  Res Theory Nurs Pract       Date:  2003       Impact factor: 0.688

10.  Efficacy of risperidone for prevention of postoperative delirium in cardiac surgery.

Authors:  U Prakanrattana; S Prapaitrakool
Journal:  Anaesth Intensive Care       Date:  2007-10       Impact factor: 1.669

View more
  5 in total

1.  Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial.

Authors:  Maurice J D L van der Vorst; Elisabeth C W Neefjes; Manon S A Boddaert; Bea A T T Verdegaal; Aart Beeker; Saskia C C Teunissen; Aartjan T F Beekman; Janneke A Wilschut; Johannes Berkhof; Wouter W A Zuurmond; Henk M W Verheul
Journal:  Oncologist       Date:  2019-12-04

2.  A systematic review of the overlap of fluid biomarkers in delirium and advanced cancer-related syndromes.

Authors:  Ingrid Amgarth-Duff; Annmarie Hosie; Gideon Caplan; Meera Agar
Journal:  BMC Psychiatry       Date:  2020-04-22       Impact factor: 3.630

3.  Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial.

Authors:  Maurice J D L van der Vorst; Elisabeth C W Neefjes; Manon S A Boddaert; Bea A T T Verdegaal; Aart Beeker; Saskia C C Teunissen; Aartjan T F Beekman; Janneke A Wilschut; Johannes Berkhof; Wouter W A Zuurmond; Henk M W Verheul
Journal:  Oncologist       Date:  2019-12-08

4.  Systematic literature review of machine learning methods used in the analysis of real-world data for patient-provider decision making.

Authors:  Alan Brnabic; Lisa M Hess
Journal:  BMC Med Inform Decis Mak       Date:  2021-02-15       Impact factor: 2.796

Review 5.  The detection of delirium in admitted oncology patients: a scoping review.

Authors:  Megan B Sands; Ian Wee; Meera Agar; Janette L Vardy
Journal:  Eur Geriatr Med       Date:  2022-01-15       Impact factor: 1.710

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.